ONESOURCE SPECL PHARMA L vs SUN PHARMACEUTICAL IND L

A side-by-side comparison of ONESOURCE SPECL PHARMA L (ONESOURCE) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads ONESOURCE vs SUNPHARMA on 10 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
40.40
3.32
P/B ratio
5.57
0.00%
Dividend yield
0.83%
₹-6.44
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

-1.09%
Return on equity
16.00%
1.00%
Return on capital
21.00%
21.00%
EBITDA margin
30.00%
-5.20%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

231.60%
Revenue CAGR (3Y)
10.03%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹18,766 Cr
Market cap
₹4.64L Cr
₹1,422 Cr
Revenue
₹58,462 Cr
₹-74 Cr
Net profit
₹11,509 Cr
0.26
Debt / equity
0.06
ONESOURCE SPECL PHARMA L
  • ["Stock is trading at 3.20 times its book value", "Company has low interest coverage ratio.", "Company has a low return on equity of -2.39% over last 3 years.", "Promoters have pledged 38.4% of their holding.", "Company has high debtors of 177 days."]
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
ONESOURCE SPECL PHARMA L full analysis SUN PHARMACEUTICAL IND L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.